These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Voretigene neparvovec for inherited retinal dystrophy due to RPE65 mutations: a scoping review of eligibility and treatment challenges from clinical trials to real practice. Testa F; Bacci G; Falsini B; Iarossi G; Melillo P; Mucciolo DP; Murro V; Salvetti AP; Sodi A; Staurenghi G; Simonelli F Eye (Lond); 2024 Sep; 38(13):2504-2515. PubMed ID: 38627549 [TBL] [Abstract][Full Text] [Related]
23. Voretigene neparvovec-rzyl for treatment of Ciulla TA; Hussain RM; Berrocal AM; Nagiel A Expert Opin Biol Ther; 2020 Jun; 20(6):565-578. PubMed ID: 32149547 [No Abstract] [Full Text] [Related]
24. Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65 Mutation-Associated Inherited Retinal Dystrophy: Results of Phase 1 and 3 Trials. Maguire AM; Russell S; Wellman JA; Chung DC; Yu ZF; Tillman A; Wittes J; Pappas J; Elci O; Marshall KA; McCague S; Reichert H; Davis M; Simonelli F; Leroy BP; Wright JF; High KA; Bennett J Ophthalmology; 2019 Sep; 126(9):1273-1285. PubMed ID: 31443789 [TBL] [Abstract][Full Text] [Related]
25. Lessons Learned from the Development of the First FDA-Approved Gene Therapy Drug, Voretigene Neparvovec-rzyl. Bennett J; Maguire AM Cold Spring Harb Perspect Med; 2023 May; 13(5):. PubMed ID: 36167727 [TBL] [Abstract][Full Text] [Related]
26. Inherited retinal diseases: Therapeutics, clinical trials and end points-A review. Georgiou M; Fujinami K; Michaelides M Clin Exp Ophthalmol; 2021 Apr; 49(3):270-288. PubMed ID: 33686777 [TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Russell S; Bennett J; Wellman JA; Chung DC; Yu ZF; Tillman A; Wittes J; Pappas J; Elci O; McCague S; Cross D; Marshall KA; Walshire J; Kehoe TL; Reichert H; Davis M; Raffini L; George LA; Hudson FP; Dingfield L; Zhu X; Haller JA; Sohn EH; Mahajan VB; Pfeifer W; Weckmann M; Johnson C; Gewaily D; Drack A; Stone E; Wachtel K; Simonelli F; Leroy BP; Wright JF; High KA; Maguire AM Lancet; 2017 Aug; 390(10097):849-860. PubMed ID: 28712537 [TBL] [Abstract][Full Text] [Related]
29. Current Management of Patients with RPE65 Mutation-Associated Inherited Retinal Degenerations in Europe: Results of a Multinational Survey by the European Vision Institute Clinical Research Network. Lorenz B; Tavares J; van den Born LI; Marques JP; Scholl HPN; Ophthalmic Res; 2021; 64(5):740-753. PubMed ID: 33684911 [TBL] [Abstract][Full Text] [Related]
30. Leber congenital amaurosis/early-onset severe retinal dystrophy: current management and clinical trials. Daich Varela M; Cabral de Guimaraes TA; Georgiou M; Michaelides M Br J Ophthalmol; 2022 Apr; 106(4):445-451. PubMed ID: 33712480 [TBL] [Abstract][Full Text] [Related]
31. Short term morphological rescue of the fovea after gene therapy with voretigene neparvovec. Kortüm FC; Kempf M; Jung R; Kohl S; Ott S; Kortuem C; Sting K; Stingl K Acta Ophthalmol; 2022 May; 100(3):e807-e812. PubMed ID: 34289237 [TBL] [Abstract][Full Text] [Related]
34. Utility of In Vitro Mutagenesis of RPE65 Protein for Verification of Mutational Pathogenicity Before Gene Therapy. Yang U; Gentleman S; Gai X; Gorin MB; Borchert MS; Lee TC; Villanueva A; Koenekoop R; Maguire AM; Bennett J; Redmond TM; Nagiel A JAMA Ophthalmol; 2019 Dec; 137(12):1381-1388. PubMed ID: 31580392 [TBL] [Abstract][Full Text] [Related]
35. New Editing Tools for Gene Therapy in Inherited Retinal Dystrophies. Pulman J; Sahel JA; Dalkara D CRISPR J; 2022 Jun; 5(3):377-388. PubMed ID: 35506982 [TBL] [Abstract][Full Text] [Related]
36. Leber congenital amaurosis/early-onset severe retinal dystrophy: clinical features, molecular genetics and therapeutic interventions. Kumaran N; Moore AT; Weleber RG; Michaelides M Br J Ophthalmol; 2017 Sep; 101(9):1147-1154. PubMed ID: 28689169 [TBL] [Abstract][Full Text] [Related]
37. Available Evidence on Leber Congenital Amaurosis and Gene Therapy. Alkharashi M; Fulton AB Semin Ophthalmol; 2017; 32(1):14-21. PubMed ID: 27686653 [TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of Voretigene Neparvovec-rzyl vs Standard Care for RPE65-Mediated Inherited Retinal Disease. Johnson S; Buessing M; O'Connell T; Pitluck S; Ciulla TA JAMA Ophthalmol; 2019 Oct; 137(10):1115-1123. PubMed ID: 31318398 [TBL] [Abstract][Full Text] [Related]
39. [Implementation of a new gene therapy in ophthalmology: Regulatory and organizational issues]. Daruich A; Boinet R; Falcou C; Cotteret C; Magassa A; Schlatter J; Escalup R; Cisternino S; Valleix S; Robert MP; Bremond-Gignac D J Fr Ophtalmol; 2021 May; 44(5):730-737. PubMed ID: 33838946 [TBL] [Abstract][Full Text] [Related]
40. Surgical Observations From the First 120 Cases of Subretinal Gene Therapy for Inherited Retinal Diseases. Gregori NZ; Davis JL Retina; 2023 Sep; 43(9):1608-1611. PubMed ID: 33394965 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]